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A standard approach to biomarker research is to retro-
spectively examine interactions between biomarkers and
treatment effects. An alternative approach of examining
such interactions prospectively has advantages. First, if
the biomarker information is required for randomization
then eliminates missing biomarker information. Another
is that nonresponding biomarker subtypes in a multi-
armed trial that do not respond to a particular arm can
be excluded from that arm, perhaps gradually, using
adaptive randomization. A consequence of adaptively
excluding nonresponders is the potential to have a smal-
ler, more focused trial.
There are limitations to such an approach. One is that
the biomarker has to be available to enable adapting to
the accumulating evidence. Another is that the outcome
database must be updated in a reasonably timing fash-
ion, and it must be connected it to the patient assign-
ment algorithm. In addition, the design, although fully
prospective, is complicated to convey to investigators,
patients, and IRBs, IECs, and other regulators.
A third possible design is to restrict trial eligibility to
the population that is the drug’s target. This is efficient,
but it relies on knowing the target. This design gives no
information about biomarker by treatment interactions.
And it inhibits learning about the roles of other
biomarkers.
The adaptive approach is a compromise between the
first and third approaches: Start with all-comers but
restrict to the responding population as the trial results
accumulate.
The approaches I describe employ randomization. All
have an adaptive aspect in which accumulating trial
results are analyzed frequently with the possibility of
modifying the trial’s future course. Many treatment
arms are possible, including combination therapies. So it
is possible to learn about the way treatments interact
with each other as well as the way they interact with
biomarkers.
Having multiple biomarkers and multiple treatment
arms increases the false-positive rate. Therefore it is
essential to prospectively build some level of confirma-
tion into the design.
False-positive rates and statistical power can be evalu-
ated by simulation and controlled.
Taking an adaptive approach is fruitless without infor-
mation to which to adapt. There is little information
available when the endpoints are long-term. However,
early markers of therapeutic effect (longitudinal biomar-
kers, measurements of tumor burden, etc.) can be corre-
lated with long-term clinical outcome.
I will give an example (called I-SPY 2) of an adaptive
biomarker-driven trial in neoadjuvant breast cancer. The
goal is to efficiently identify biomarker signatures for a
variety of agents and combinations being considered
simultaneously.
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